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Background: Perioperatory chemoradiotherapy (CRT) improves local control and survival in patients with locally
advanced rectal cancer (LARC). The objective of the current study was to evaluate the addition of bevacizumab
(BEV) to preoperative capecitabine (CAP)-based CRT in LARC, and to explore biomarkers for downstaging.
Methods: Patients (pts) were randomized to receive 5 weeks of radiotherapy 45 Gy/25 fractions with concurrent
CAP 825 mg/m2 twice daily 5 days per week and BEV 5 mg/kg once every 2 weeks (3 doses) (arm A), or the same
schedule without BEV (arm B). The primary end point was pathologic complete response (ypCR: ypT0N0).
Results: Ninety pts were included in arm A (44) or arm B (46). Grade 3–4 treatment-related toxicity rates were 16%
and 13%, respectively. All patients but one (arm A) proceeded to surgery. The ypCR rate was 16% in arm A and 11%
in arm B (p =0.54). Fifty-nine percent vs 39% of pts achieved T-downstaging (arm A vs arm B; p =0.04). Serial
samples for biomarker analyses were obtained for 50 out of 90 randomized pts (arm A/B: 22/28). Plasma
angiopoietin-2 (Ang-2) levels decreased in arm A and increased in arm B (p <0.05 at all time points). Decrease in
Ang-2 levels from baseline to day 57 was significantly associated with tumor downstaging (p =0.02).
Conclusions: The addition of BEV to CAP-based preoperative CRT has shown to be feasible in LARC. The association
between decreasing Ang-2 levels and tumor downstaging should be further validated in customized studies.
Trial registry: Clinicaltrials.gov identifier NCT01043484. Trial registration date: 12/30/2009.
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Surgery is the mainstay of curative therapy for patients
with rectal cancer confined to the bowel and regional
lymph nodes. Nevertheless, rectal cancers have a high
incidence of local failure. Recurrent pelvic disease is as-
sociated with significant morbidity and substantially
shorter survival [1]. Perioperatory chemoradiotherapy
(CRT) improves local control and survival in patients
with locally advanced (T3-T4) rectal cancer (LARC) [2].* Correspondence: ramonsalazar@iconcologia.net
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unless otherwise stated.Moreover, this strategy maximizes downstaging, in-
creases the rate of sphincter-sparing surgery and pro-
vides early exposure to systemic therapy.
Capecitabine is being integrated into the treatment of
patients with colorectal cancer as an alternative to 5-
fluorouracil (5-FU), resulting in improved convenience
without compromising efficacy [3]. In addition, radiation
induces thymidine phosphorylase and enhances the effi-
cacy of capecitabine, leading to a synergistic effect [4]. A
recent non-inferiority phase III study has shown capecit-
abine can replace 5-FU in adjuvant or neoadjuvant CRT
regimens for patients with LARC [5].This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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chemoradiation have shown promising results [6-11],
but the lack of randomization and the bias associated
with single-arm trials raises important concerns when
interpreting these data. No randomized study to date
has tested the use of bevacizumab in the neoadjuvant
setting for localized disease.
Based on our previous experience (back to back submis-
sion [12]) and reports of preliminary feasibility of bevaci-
zumab and chemoradiation in rectal cancer, we conducted
a randomized trial of neoadjuvant bevacizumab and che-
moradiation in patients with resectable LARC. Also, as lit-
tle data exists on the role of biomarkers as predictors of
response to bevacizumab when adding to preoperative
CRT in LARC, we explored potential biomarkers that have
been previously found to change in response to bevacizu-
mab in other translational trials [11,13-20].
The following possible prognostic factors for tumor
angiogenesis were evaluated: vascular endothelial growth
factor (VEGF) and circulating soluble VEGF receptor 2
(VEGFR-2) which can be expressed in malignant tumors
[21], angiopoietin-2 (Ang-2) expression, a molecule which
promotes destabilization of blood vessels, and whose ex-
pression decreases along with microvessel density (MVD)
after bevacizumab administration supporting the theory
on the normalization of the vessels postulated for that
drug [18], and the intratumor MVD since an increase in
the number of tumor vessels might constitute a higher risk
to develop metastasis [22-25].
Methods
This open, multicenter randomized phase II trial was
carried out by the Spanish Cooperative Group for the
Treatment of Digestive Tumors (TTD group). The study
was conducted in accordance with the Declaration of
Helsinki and Good Clinical Practice Guidelines. Before
starting the study, written informed consent was ob-
tained from all patients in the study. The protocol was
approved by the institutional review boards of all partici-
pating centers. Reference Ethic Committee: Comité Ético
de Investigación Clínica del Hospital Universitario 12 de
Octubre, Avda de Córdoba, s/n, 28041 Madrid.
Patient selection
Patients 18 years of age or older with locally advanced rec-
tal adenocarcinoma, clinical stage II-III [American Joint
Committee on Cancer version 6: pelvic magnetic resonance
imaging (MRI) was used to define T category and N cat-
egory], within <15 cm from the anal verge, and an Eastern
Cooperative Oncology Group (ECOG) performance status
of 0 or 1 were eligible. All patients were required to be can-
didates for definitive surgical resection. Patients had ad-
equate bone marrow and organ function and no previous
chemotherapy or radiation for rectal cancer. Exclusioncriteria included uncontrolled hypertension, clinically signi-
ficant cardiac disease, having undergone major surgery
within 28 d of trial therapy, recent or current use of full-
dose oral or parenteral anticoagulants or thrombolytic
agents, chronic daily treatment with high-dose aspirin, or
treatment with nonsteroidal anti-inflammatory drugs.
Treatment schedule
Patients were randomly allocated in a 1:1 ratio to CRT
treatment with or without bevacizumab, using permuted
blocks with stratification by center and tumor location
(upper or middle third vs lower third). Radiotherapy (RT)
consisted of a total of 45 Gy delivered in 25 daily fractions
over 5 weeks (1.8 Gy/d for 5 d/wk). Patients in arm A re-
ceived concomitant bevacizumab (5 mg/kg) on day 1 of
weeks 1, 3, and 5, plus capecitabine (825 mg/m2) twice
daily concomitant with RT; the same schedule without
bevacizumab was administered to patients in arm B. One
cycle was considered two weeks for cycle 1 and 2, and one
week for cycle 3. Standard surgery, , was performed 6–8
weeks after the completion of CRT. A radical resection of
the rectal tumor along with an appropriate vascular ped-
icle and accompanying lymphatic drainage was made. For
tumors in the mid and lower rectum total mesorectal exci-
sion (TME) was carried out. However, for tumors in the
upper rectum (at or above 10 cm from the anal margin)
the mesorectum was resected at 5 cm or more distal to
the tumor. Postoperative adjuvant chemotherapy was ad-
ministered at the investigators discretion.
The protocol stipulated detailed capecitabine dose-
modification criteria according to toxicity, graded using
the National Cancer Institute Common Toxicity Criteria
(NCI-CTC) version 3.0. No dose reductions for bevaci-
zumab were planned.
Evaluations during the study
Pretreatment evaluation included a complete medical
history and physical examination, hematology with dif-
ferential leucocyte count, chemistry, coagulation profile,
urinalysis, carcinoembryonic antigen, electrocardiogram,
complete colonoscopy with biopsy, abdominal and thor-
acic computerized axial tomography (or thoracic x-ray),
and pelvic MRI. Medical history, physical examination,
and laboratory studies were repeated prior to the start of
each treatment cycle (days 1, 15 and 29 ± 2 days). After
surgery, histologic tumor infiltration (ypTypN) and grad-
ing of regression [assessed using the Mandard scale [26]]
were evaluated.
All patients were scheduled for a follow-up period of
5 years after surgery.
Biologics evaluation
Participation in the biologic sub-study was optional. To
those patients who gave their consent to have the
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and Ang-2 were measured at baseline (d1, pre-treatment),
15 (d15) and 57 days (d57, post-treatment) after first treat-
ment infusion by enzyme-linked immunosorbent assay
(ELISA): Quantikine Immunoassays (R&D Systems) were
used according to the manufacturer’s instructions.
Additionally, tissue samples (baseline and at surgery)
were assessed for MVD by immunohistochemistry, as
described previously [27].
Statistical analysis
The primary end-point was pathological complete re-
sponse (pCR), as defined by ypT0N0. Based on previous
trials, a conservative estimate of pCR rate for patients with
LARC treated with capecitabine and radiation is approxi-
mately 15% [28-35]. Following the SWE method for ran-
domized phase II clinical trials [36], assuming a minimum
pCR rate of at least 15% in one of the arms, a difference
between the two arms of 10%, and accepting a probability
of correct selection of 87%, 41 pts per arm were needed.
Considering a 10% of non-evaluable patients, the study
needed to enroll a minimum of 90 patients.
The primary efficacy analyses were conducted on an
intention to treat (ITT) basis (all randomized patients).
The safety analysis was performed for the safety popula-
tion (patients who initiated trial therapy). The statistical
analyses were performed using SAS version 9.2.
The pCR rate was calculated and the 95% confidence in-
tervals (CI) were estimated using normal approximation.Figure 1 CONSORT diagram.Secondary end-points were safety, and rates of downstaging
(lower ypT compared with the pretreatment clinical T),
sphinctersparing surgery, local recurrence, post-surgical
complication and of complete resection (R0). Proportions
were compared using a χ2 test or, if this could not be used,
a Fisher’s exact test.
All statistical tests were two-sided. The significance
level was established at a value of α =0.05.
The intra-individual differences at different time points
for the concentrations of biomarkers were tested through
paired t-Test if the population was normally distributed,
or else through Wilcoxon signed rank test. To test these
differences between groups of treatment, Student test was
used if the distribution was normal, and Mann–Whitney
test if it was not normally distributed.
Logistic regression model was adopted to estimate and
test the biomarkers for their association with downsta-
ging. Results were expressed as odds ratios and their
95% CI. Data analysis is reported according to REMARK
guidelines [37].Results
Between December 2009 and March 2011, 90 patients
were randomly assigned through 12 Spanish hospitals,
44 in arm A and 46 in arm B (Figure 1).
Baseline patient characteristics were well balanced be-
tween groups (Table 1). The median distance from anal
verge was 6.5 cm in arm A and 7.0 cm in arm B.
Table 1 Baseline characteristics: intention to treat
population (n = 90)
Arm A Arm B
(BVZ + CAP + RT) (CAP + RT)
(n° patients = 44) (n° patients = 46)
Parameter No. of patients % No. of patients %
Sex
Male 25 57 30 65





0 22 50 30 65
1 22 50 16 35
Tumor location
Upper third 10 23 10 22
Middle third 14 32 19 41
Lower third 20 45 16 35
Unknown 0 0 1 2
Clinical tumor category
T2 1 2 1 2
T3 33 75 38 83
T4 10 23 7 15
Clinical nodal category
N0 7 16 5 11
N1 18 41 27 59
N2 19 43 14 30
Clinical TNM
IIA 6 14 5 11
IIB 1 2 0 0
IIIB 18 41 27 59
IIIC 19 43 14 30
Table 2 Early adverse events relateda to treatment
(≥10%) per patient (%) according to NCI-CTC criteria v3.0
Arm A Arm B
(BVZ + CAP + RT) (CAP + RT)
(n° patients = 44) (n° patients = 46)
% grade 1/2 % grade 3 % grade 1/2 % grade 3
Astenia/fatigue 55 2 24 -
Diarrhea 36 - 41 -
Dysuria 18 - 30 -
Rectal tenesmus 18 - 17 -
Nausea 13 - 11 -
Hand-foot
syndrome
14 - 4 2
Anorectal
discomfort
9 2 9 -
Anorexia 9 - 11 -
Note: there were no grade 4 events.
aAn adverse event was considered attributable to bevacizumab, capecitabine
or radiation if it was deemed remotely, possibly or probably related.
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Treatment compliance was similar in both arms. Forty-
one (93%) and forty-three (93%) patients completed the
planned CRT treatment in arm A and arm B, respectively.
Five patients received a dose of RT of lower than 45 Gy, 3
in arm A (1 of them discontinued the treatment after receiv-
ing 30.6 Gy, due to toxicity) and 2 in arm B. Two patients in
arm A and three patients in arm B received <3 cycles of cape-
citabine, due to toxicity; a dose reduction of capecitabine was
performed in 1 patient (toxicity). In arm A, all but one pa-
tient (toxicity) received the planned 3 cycles of bevacizumab.
Safety
Treatment-related toxicity occurring at a frequency >10%
of patients is summarized in Table 2. The overall rate ofpatients with grade 3 to 4 treatment-related toxicity was
16% in arm A versus 13% in arm B (p =0.70). There was
no grade 3 or greater hematological toxicity. Three pa-
tients in arm A (grade ≤ 2) and two in arm B (one grade 1
and another grade 3) had hypertension, two of them con-
sidered as probably related to the study treatment (arm A).
Surgery was performed after a median interval of 51 days
(range, 36–100 days). All included patients but one (arm A:
peritoneal carcinomatosis) proceeded to surgery. Anterior
resection and abdominoperineal resection were performed
in 27 (61%) and 15 patients (34%) in arm A and in 31
(67%) and 13 patients (28%) in arm B, respectively: other
procedures were performed in the remaining patients.
Thirty-four (77%) patients in arm A and 36 (78%) in arm B
underwent TME: the remaining patients undergoing sur-
gery (9 in arm A and 10 in arm B) had a partial mesorectal
excision (PME) due to their tumors were located at the
upper rectum. Sphincter preservation was achieved in 27
(61%) and 31 (67%) patients in arm A and B, respectively.
The overall rate of surgical complications was not signifi-
cantly different between groups. Two patients in arm A
and 6 patients in arm B experienced local complications.
Nineteen patients (43%) and 18 (39%) patients in arm A
and B experienced at least one postoperative complication,
respectively. Ten patients (7 in arm A (15.9%) and 3 in arm
B (6.5%)) required reoperation, due to anastomotic dehis-
cence. There were no perioperative deaths. During surgery,
distant metastases in abdomen were found in 4 patients, all
of them in arm B.
Response to treatment
The ypCR (ypT0N0) rate in the ITT population was 16%
(7/44 patients; 95% CI 7-31%) in arm A and 11% (5/46
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residual tumor (R0) was achieved in all except 3 pa-
tients, who had microscopic residual disease (R1). Six-
teen (36%) patients in arm A and 20 (44%) patients in
arm B attained Mandard tumor regression grade (TRG)
1 or 2 responses. A decrease in the T stage (T downsta-
ging) was achieved by 26 (59%) of 43 operated patients
in arm A versus 18 (39%) of 46 in arm B (p =0.04)
(Table 3).
After a median follow-up of 18 months (range, 3–28
months), 88 (98%) patients remained alive, and 73 (81%)
patients continued to be free of any sign of disease. One
patient in arm B had a local recurrence, six patients in
each arm developed distant metastases, four patients in
arm B presented a second tumor (one of them was the
patient with local recurrence), and two patients in arm
A had died due to the underlying cancer (one of them
had presented distant metastases).
Study of prognostic factors
At the time of analysis, biomarker outcome data were
available for 50 of the 90 randomized patients (56% of
trial participants), 22/44 (50%) treated in arm A and 28/
46 (61%) in arm B. At least paired plasma samples wereTable 3 T and N downstaging (intention to treat
population: 90 patients)
Arm A Arm B p value
(BVZ + CAP + RT) (CAP + RT)







Better 26 59 18 39
Equal 16 37 28 61
Worse 1 2 0 0
Missinga 1 2 0 0
ypN 0.0865
Better 24 55 35 76
Equal 15 34 8 18
Worse 4 9 2 4
No Evaluableb 0 0 1 2
Missinga 1 2 0 0
ypT and ypN 0.5612
Better in both 18 41 16 35
Better in one of
them
14 32 20 43
Worse in both 11 25 9 20
No Evaluableb 0 0 1 2
Missinga 1 2 0 0
aNo surgery.
bIt was reported as ypNx.available for 18 patients in arm A and 23 in arm B;
tumor samples (pretreatment and from surgical speci-
men) were available from 12 and 18 patients in arm A
and B, respectively (Figure 2).
Downstaging was evaluated in 49 out of the 50 pa-
tients included in the sub-study: one patient did not
undergo surgery. Eleven patients in each arm were
downstaged: no statistically significant differences were
observed between groups (p =0.36).
No differences were observed in baseline levels of any
biomarker between both arms. The pretreatment level of
biomarkers showed no association with downstaging.
Angiopoietin-2 levels were significantly higher in arm B
than in arm A at d15 (p =0.0056) and d57 (p =0.0133)
(Table 4). Angiopoietin-2 levels significantly decreased in
arm A at d15 (p =0.04) and increased in arm B (p =0.01)
at d57. When intergroup differences were studied, plasma
Ang-2 levels decreased in arm A and increased in arm B
at all time points compared to baseline level, with signifi-
cant differences between levels in group A and B at all
time points. Overall, decrease in Ang-2 levels from base-
line to d57, was significantly associated with tumor down-
staging (OR: 0.95, 95% CI 0.91-0.99; p =0.02).
In contrast to serum Ang-2, VEGF levels increased in
arm A and decreased in arm B at all time points com-
pared to baseline levels, with significant intergroup dif-
ferences at all time points. Nevertheless, there was no
significant association between serum VEGF levels and
downstaging.
There were no significant changes in other biomarker
levels and none was associated with tumor downstaging.
Discussion
This study confirms the feasibility of preoperative CRT
with bevacizumab and capecitabine in patients with
LARC, in a randomized trial. Although the patients who
received bevacizumab tended to have a higher pCR rate,
the predefined efficacy endpoint was not met. Interesting,
Ang-2 plasma levels significantly decreased along the
study in patients receiving bevacizumab and, overall, de-
crease in Ang-2 levels was significantly associated with
tumor downstaging: those findings suggest improved
tumor shrinkage related to the use of bevacizumab and a
potential role of plasma Ang-2 to monitor downstaging.
We conducted this study to further understand the
role of bevacizumab in the treatment of LACR. The
5 mg/kg dose was chosen based on the toxicity observed
in the Willet et al. study [18], and the Xeberecto Trial
(back to back submission [12]), a phase II study of pre-
operative bevacizumab, capecitabine and radiotherapy
for resectable LARC. Our trial was initially designed to
include oxaliplatin in both arms; however because the
results of two large randomized studies [38,39] did not
demonstrate the benefit of oxaliplatin with concurrent
Figure 2 Plasma and tumor samples availability for biomarker analyses.
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drug.
Our patients had a relatively high risk for pelvic re-
currence (98% were T3 or T4, and 87% were N+). The
reached pCR rate of 16%, albeit not too high, is within the
range (13-36%) reported across a number of phase II stud-
ies evaluating bevacizumab plus CRT (Table 5) [6-11].
However, caution is needed when comparing pCR rates as
this item itself is highly dependent on the quality of the
pathological examination [40].
The decrease in the T stage was significantly higher in
patients receiving bevacizumab, although the rate of
downstaging in both arms was lower than in other single
arm studies using preoperative bevacizumab plus CRT
[6,10,11]. This should be interpreted with caution be-
cause of the preoperative MRI staging technical limita-
tion and lack of central imaging evaluation.Table 4 Evolution of biomarkers during the study compared
Arm A
(BVZ + CAP + RT)
VEGF VEGFR-2 Ang-2 MV
Basal
n 18 18 18 12
Median 56 9056 2424 14
p NA NA NA NA
D15a
n 18 18 18 12
Median 13 7 −22 −8
p 0.19 0.18 0.04 0.7
D57a
n 14 14 13 NA
Median 55 7 −16 NA
p 0.03 0.20 0.20 NA
Abbreviations: IQR interquartile range, VEGF vascular endothelial growth factor, VEGF
aPercent difference (%) = [(Later value- Basal value)/Basal value] × 100.
bTissue samples (baseline and at surgery).Toxicities were expected and manageable. Early toxicity
was mild in both arms. The most serious post-operative
complication was anastomotic dehiscence, which occurred
more frequently in patients treated with bevacizumab, but
in the range reported by others [6,7,9-11].
Suitable biomarkers predicting patients who are likely to
benefit from bevacizumab treatment remain elusive [41].
In our exploratory analyses decrease in Ang-2 levels from
baseline to d57 was significantly associated with tumor
downstaging. Moreover, Ang-2 levels decreased in the
bevacizumab arm and increased in the other arm at all
time points compared to baseline levels, with significant
differences between levels in both groups at all time
points. Angiopoietin-2 has been proposed as a gatekeeper
of VEGF function and vascular remodeling [42,43], and
has been shown to promote metastatic growth [44]. Goede
et al. [14] found that serum levels of Ang-2 in patientsto pretreatment (basal) value
Arm B
(CAP + RT)
Db VEGF VEGFR-2 Ang-2 MVDb
23 23 23 18
85 9282 3609 14
NA NA NA NA
23 23 23 18
−40 4 16 34
3 0.11 0.33 0.11 0.03
17 17 17 NA
−13 −2 20 NA
0.71 0.86 0.01 NA
R-2 circulating soluble VEGF receptor 2, Ang-2 angiopoietin-2.
Table 5 Clinical trials of bevacizumab + radiochemotherapy as pre-operative treatment of locally advanced rectal
cancer
Author and regimen No. of patients pCR (yp T0-N0; %) T-downstaging (%) Grade 3 most common toxicities
Willet [11]
BVZ + 5FU + RT 32 16a 50 Diarrhea and hypertension
Spigel [9]
BVZ + 5FU + RT 35 29 NA Diarrhea
Crane [6]
BVZ + CAP + RT 25 32 64 Perianal desquamation
Velenik [10]
BVZ + CAP + RT 61 13 45 Dermatitis
Kennecke [7]
BVZ + CAP + OX + RT 42 18 NA Diarrhea
Nogue [8]
BVZ + XELOX→ BVZ + CAP + RT 47 36 NA Rectal tenesmus
Salazar (current study)
BVZ + CAP + RT 44 16 26 Astenia/fatigue
CAP + RT 46 11 18
Abbreviations: pCR pathological complete response, BVZ bevacizumab, 5FU 5-fluorouracil, CAP capecitabine, OX oxaliplatin, XELOX capecitabine + oxaliplatin,
RT radiotherapy, NA not available.
aypT0.
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than in healthy individuals: moreover, in that study, com-
pared with high serum Ang-2 levels, low serum Ang-2
was associated with an outstanding response rate, better
disease control and excellent overall survival (OS). Al-
though one can only speculate about this relationship, it
seems plausible that adding bevacizumab to standard CRT
induces a decrease in serum Ang-2 levels that could facili-
tate tumor regression.
On the contrary, we found that serum VEGF levels in-
creased in arm A and decreased in arm B at all time
points compared to baseline levels, with significant inter-
group differences at all time points: this finding had not
influence on downstaging. Similarly, several studies have
shown acute increases in circulating VEGF after the start
of bevacizumab [11]. Nevertheless, changes in VEGF
concentrations associated with bevacizumab treatment
have not necessarily been predictive of benefit [41]. De-
tailed analyses are needed of total and free VEGF levels
during treatment before circulating VEGF is dismissed
as a biomarker.
In accordance with previous reports [11,12,14,45], pre-
treatment level of VEGF and tumor MVD was not corre-
lated to clinical end points.
This trial has several limitations. Firstly, the selection of
patients for the biologic sub-study was opportunistic, by
including those patients who gave their consent and in
which assessment of selected biomarkers was available at
different points, although there is no reason to suspectany differences with other patients where those determi-
nations were not possible. Secondly, the small size of each
cohort in that study makes it difficult to find potential as-
sociations between changes in different biomarkers, and
comparisons between both arms: nevertheless, our find-
ings point in the same direction as that described by other
authors. Thirdly, TME was not possible in around 20% of
patients, due to the tumor localization: as stated previ-
ously [5], TME was mandatory for tumors in the lower
two-thirds of the rectum, with PME being permitted for
those in the upper third, provided a distal margin of at
least 5 cm without coning was observed. Finally, as in
other studies realized in patients with LARC, 4 patients
were found having distant metastases at the time of sur-
gery, a number not very different of those published by
others [39]. As we didn’t make a reevaluation of the base-
line studies, we cannot discharge a possible mistake in the
inclusion of any patient.
Conclusions
The results of this randomized study support the data de-
scribed previously in single arm studies about the feasi-
bility of the addition of bevacizumab to a standard
neoadjuvant capecitabine-based CRT regimen, as well as
its potential role in downstaging. It will be also important
to continue observation of these patients to elucidate
long-term outcome and morbidity of this strategy. Fur-
thermore, although definitive judgment on the role of
Ang-2 as a specific biomarker of outcome to bevacizumab
Salazar et al. BMC Cancer  (2015) 15:60 Page 8 of 9in LARC will require further analysis of larger numbers of
patients from phase III trials, the results arising from this
study should encourage researchers to further investigate
the value of Ang-2 amongst others as a potential bio-
marker to monitor the added value of bevacizumab in
clinically relevant endpoints.
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